Grant: Institute of Genetics Clinical Investigatorship Award
University of Calgary
$280,000.00
Pharmacogenetics of juvenile idiopathic arthritis - A genome wide association study on the efficacy and toxicity of methotrexate therapy
EF 2010-11
Résumé
Methotrexate is the most commonly used immunosuppressive medication for children with chronic arthritis. This research focuses on identifying key gene variants that predict response to methotrexate and treatment-related toxicity. An international partnership of expert physicians and researchers in childhood arthritis was established. Children will be carefully characterized in their arthritis and response to methotrexate therapy. The child's genetic make-up will be determined from simple spit samples and correlated with treatment response and side effects. The results of the study will enable physicians to optimise childhood arthritis therapy and prevent medication side effects by tailoring medications towards the individual genetic make-up.
Programme
Institute of Genetics Clinical Investigatorship Award
Bénéficiaire
Emplacement
Alberta, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database
Tel que publié
Id
209212
Name
Schmeling Heinrike
Region
Alberta
Country
Canada
Orgtype
Institution Paid; Research Institution
Instname2
Genetics
Theme2
Clinical
Prcname2
Institute of Genetics Clinical Investigatorship
Projecttitle
Pharmacogenetics of juvenile idiopathic arthritis - A genome wide association study on the efficacy and toxicity of methotrexate therapy
Programtype2
Salary Programs
Orgnameinp2
University of Calgary
Cihramount2
$280,000
Cihrequipment2
$0
Programname2
Institute of Genetics Clinical Investigatorship Award
Keyworddelim
Childhood Arthritis; Methotrexate; Pharmacogenetics
Abstract
Methotrexate is the most commonly used immunosuppressive medication for children with chronic arthritis. This research focuses on identifying key gene variants that predict response to methotrexate and treatment-related toxicity. An international partnership of expert physicians and researchers in childhood arthritis was established. Children will be carefully characterized in their arthritis and response to methotrexate therapy. The child's genetic make-up will be determined from simple spit samples and correlated with treatment response and side effects. The results of the study will enable physicians to optimise childhood arthritis therapy and prevent medication side effects by tailoring medications towards the individual genetic make-up.
Competitiondate
201007
Approvedterm2
2 yrs 0 mth
Pinamesdelim
Schmeling, Heinrike
Approvedterm
2 ans 0 mois
Cihrcontribution2
Inst of Musculoskel Hlth &Arth~ $140,000~ $0~Institute of Genetics~ $140,000~ $0~
